INmune BioINMB -4.59%52 Forward Dividend Yield % is 0.00% as of Jun. 24, 2026. GuruFocus rates INMB with a GF Score™ of 52/100 and a GF Value™ of $1.84 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 147 Biotechnology companies, INmune Bio ranks worse than 680271.43% on this metric.
As of today (2026-06-24), the Forward Annual Dividend Yield of INmune Bio is 0.00%.
As of today (2026-06-24), the Trailing Annual Dividend Yield of INmune Bio is 0.00%.
INMB's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.51 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
INmune Bio (NAS:INMB) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
INMB vs GRDX, VERU, ABVC: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, INmune Bio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INmune Bio Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, INmune Bio's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where INmune Bio's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
INmune Bio (INMB) has a Forward Dividend Yield % of 0.00% as of Jun. 24, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on INmune Bio and its competitors. According to the industry distribution chart, INmune Bio ranks #999999 out of 147 companies in the Biotechnology industry.
Is INmune Bio's Forward Dividend Yield % too high?
INmune Bio's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, INmune Bio ranks #999999 out of 147 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, INmune Bio has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's Forward Dividend Yield % compare to GRDX and VERU?
According to the Biotechnology industry distribution chart, INmune Bio ranks #999999 out of 147 companies for Forward Dividend Yield %. This places INmune Bio in the lower half of its industry. The industry median Forward Dividend Yield % is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.51, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on INmune Bio and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INmune Bio's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.84, compared to a current price of $1.35 — trading 26.6% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. INmune Bio's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For INmune Bio (INMB), the current Forward Dividend Yield % is 0.00% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INmune Bio (INMB) Overvalued in 2026?
Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued.
The current stock price of $1.35 is trading 26.6% below its estimated GF Value™ of $1.84.
GuruFocus considers INmune Bio to be Modestly Undervalued.
Key valuation signals for INMB:
Forward Dividend Yield %: 0.00%
GF Value™: $1.84 vs. price of $1.35 (26.6% below fair value)
No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
52GF Score
Get the complete analysis for INMB
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INMB has been successfully added to your 